Literature DB >> 28512687

Added Value of Covered Stents in Transjugular Intrahepatic Portosystemic Shunt: A Large Single-Center Experience.

Amar C Gupta1, Weiping Wang2, Chintan Shah3, Mark J Sands4, Jennifer Bullen5, Erick M Remer6, Pilar M Bayona4, William Carey7, Baljendra Kapoor4.   

Abstract

PURPOSE: Transjugular intrahepatic portosystemic shunts (TIPS) were historically placed using uncovered bare-metal stents. Current practice has now shifted toward the use of polytetrafluoroethylene (PTFE)-covered stents, given the improved primary patency seen with these stents. The aim of this study was to determine whether there is any added value, such as overall survival or stent patency, when using covered stents versus uncovered stents in TIPS placement in a large cohort.
MATERIALS AND METHODS: From April 1995 to June 2012, a total of 744 consecutive adult patients underwent de novo TIPS placement (378 receiving uncovered stents, 366 receiving covered stents). Information was obtained on demographics, baseline clinical variables, and outcomes after TIPS placement. Data were collected, compared, and analyzed to assess outcomes including mortality, primary patency (determined via repeat intervention), and secondary patency (determined via ultrasound parameters).
RESULTS: Covered stents were associated with significantly improved primary patency (P < 0.001) and secondary patency (P < 0.001) when compared with uncovered stents in TIPS procedures. Additionally, covered stents were associated with higher estimated overall survival rates and higher survival rates when TIPS was performed emergently and in patients with higher Model for End-Stage Liver Disease (MELD) scores. For example, in patients with MELD scores between 11 and 18, there was a predicted survival of 59.2% with covered stents versus 42.8% with uncovered stents at 1 year.
CONCLUSION: This study demonstrated that covered stents offer the additional value of higher estimated overall survival and higher estimated survival in patients undergoing TIPS emergently and in those with higher MELD scores when compared to uncovered stents.

Entities:  

Keywords:  Cirrhosis; Liver; Portal vein hypertension; Stent; TIPS

Mesh:

Substances:

Year:  2017        PMID: 28512687     DOI: 10.1007/s00270-017-1694-1

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  5 in total

Review 1.  Emergent Transjugular Intrahepatic Portosystemic Shunt Creation in Acute Variceal Bleeding.

Authors:  Mithil B Pandhi; Andrew J Kuei; Andrew J Lipnik; Ron C Gaba
Journal:  Semin Intervent Radiol       Date:  2020-03-04       Impact factor: 1.513

Review 2.  Imaging-guided interventions modulating portal venous flow: Evidence and controversies.

Authors:  Roberto Cannella; Lambros Tselikas; Fréderic Douane; François Cauchy; Pierre-Emmanuel Rautou; Rafael Duran; Maxime Ronot
Journal:  JHEP Rep       Date:  2022-04-04

Review 3.  Managing portal hypertension in patients with liver cirrhosis.

Authors:  Tilman Sauerbruch; Robert Schierwagen; Jonel Trebicka
Journal:  F1000Res       Date:  2018-05-02

4.  Outcomes of endovascular interventional therapy for primary Budd-Chiari syndrome caused by hepatic venous obstruction.

Authors:  De-Lei Cheng; Nan Zhu; Hao Xu; Cheng-Li Li; Wei-Fu Lv; Wei-Wei Fang; Chuan-Ting Li
Journal:  Exp Ther Med       Date:  2018-09-07       Impact factor: 2.447

Review 5.  Applying Principles of Regenerative Medicine to Vascular Stent Development.

Authors:  Prakash Parthiban Selvakumar; Michael Scott Rafuse; Richard Johnson; Wei Tan
Journal:  Front Bioeng Biotechnol       Date:  2022-03-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.